Abstract:The Thermo Cardiosystems Inc (Woburn, MA) HeartMate 1000 IP left ventricular assist device (LVAD) has been evaluated as a bridge to transplantation in 34 patients for up to 324 days at seven clinical centers in the United States. Sixty-five percent of the patients underwent transplantation, 80% of whom were discharged from the hospital. Six additional control patients, transplant candidates who met the entrance criteria but who did not receive the device, were also included in the study. Although 3 (50%) of the control patients received transplants, all 6 died within 77 days of having met the LVAD inclusion criteria (100% mortality). Complications resulting from use of the device were comparable with those previously reported for all ventricular assist devices, except for thromboembolic events: bleeding, 39%; infection, 25%; and right heart failure, 21%. No device-related thromboembolic events occurred, although 1 patient experienced an event related to a mechanical aortic valve in the native heart. None of the complications had a significant negative association with outcome of the patient except for right heart failure. All survivors had a significant improvement in hepatic function before transplantation. Total bilirubin values were reduced by 60% during LVAD support. No significant differences were observed when total bilirubin values were compared at 30 and 60 days after LVAD support and at 30 and 60 days after transplantation in a cohort of 15 patients (p greater than 0.05). The improvement in renal function was less predictable than that of hepatic function. Creatinine values decreased significantly before transplantation; however, the values measured at 30 and 60 days after transplantation were higher than those measured at the same intervals after LVAD support had been initiated, and this increase is presumably related to the immunosuppressive drugs. In conclusion, the HeartMate 1000 IP LVAD has been shown to be effective in supporting end-stage cardiomyopathy patients to transplantation. Thromboembolism, previously regarded as a serious complication with such devices, has not been a problem with this device. Additional patients are being enrolled into the study to further document the safety and effectiveness of this technology.

The HeartSaver left ventricular assist device: an update

Durable left ventricular assist devices: a contemporary review of their benefits and drawbacks

Evolution of Mechanical Circulatory Support for advanced heart failure

Developments and Challenges in Durable Ventricular Assist Device Technology: A Comprehensive Review with a Focus on Advancements in China

Left ventricular assist devices: yesterday, today, and tomorrow

International experience using a durable, centrifugal-flow ventricular assist device for biventricular support

Mechanical circulatory support systems: evolution, the systems and outlook

Left ventricular assist devices: A historical perspective at the intersection of medicine and engineering

Implantable ventricular assistance systems (VAD) as a bridge to transplant or as ‘destination therapy’

Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device

An in silico twin for epicardial augmentation of the failing heart

Left Ventricular Assist Device in Advanced Refractory Heart Failure: A Comprehensive Review of Patient Selection, Surgical Approaches, Complications and Future Perspectives

Electrohydraulic ventricular assist device development

Clinical effectiveness of mechanical ventricular bypass in treating postoperative heart failure

Hemodynamical Evaluation of a New Surgically Implanted Pulsatile Right Ventricular Assist Device Driven by a Conventional Intra-Aortic Balloon Pump Console

Cardiological Challenges Related to Long-Term Mechanical Circulatory Support for Advanced Heart Failure in Patients with Chronic Non-Ischemic Cardiomyopathy

Single-centre experience with the Thoratec paracorporeal ventricular assist device for patients with primary cardiac failure

When all Else Fails, Try This: The HeartMate III Left Ventricle Assist Device

Application of the moving-actuator type pump as a ventricular assist device: in vitro and in vivo studies

Current status and future directions in pediatric ventricular assist device

TriVAD: Successful use of Impella 5.5 and Protek Duo CentriMag RVAD following Heartware HVAD thrombosis as a bridge to heart transplant